Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

At the start, pembrolizumab is given over a period of time, with regular medical checks during treatment. After treatment, the cancer is checked again with tests such as a CT scan, which is a special X-ray picture of the body, and an endoscopy, which is a thin tube test used to look inside the bowel. Based on these results, some people may go on to surgery, while others may be monitored closely without immediate surgery. The study also follows health over time to learn about possible side effects, recovery, and general well-being.

The purpose of the study is to see how well NNC0487-0111 helps people with obesity lose weight and to check its safety. People in the trial will receive weekly treatment over a period of time, and the study will follow changes in body weight and other health measures during the trial. The study may also look at body size, blood pressure, blood sugar, blood fats, and signs of inflammation, as well as any side effects.

The trial is designed to compare different amounts of the study medicine with placebo, and some people may continue into an extension phase, which means treatment and follow-up may last longer. The overall study is planned to run for several years.

The purpose of this study is to see whether Tozorakimab can reduce the number of times COPD symptoms suddenly get worse, which are called exacerbations. These exacerbations are episodes when breathing problems become more severe than usual and may require additional treatment or even hospitalization. The study will compare two different amounts of Tozorakimab given as an injection under the skin to placebo, which will be added to the standard medications that participants are already taking for their COPD.

The study will last for about 52 weeks. During this time, participants will receive regular injections of either Tozorakimab or placebo, and doctors will monitor how often their COPD symptoms worsen and how severe these episodes are. The study focuses on people who have had at least two moderate episodes or one severe episode of worsening COPD symptoms in the past year, who are former smokers, and who continue to have symptoms despite using their regular COPD medications.

The study will include adults between 40 and 80 years old who have moderate to severe lung disease with frequent flare-ups, meaning they have had at least two moderate flare-ups or one severe flare-up in the past year. Participants need to have higher levels of certain white blood cells called eosinophils in their blood. They should already be using three types of inhaled medications for their lung condition, including an inhaled steroid, for at least six months before joining the study. The study will look at how often flare-ups happen during treatment and will measure this over time.

During the study, participants will receive injections of either the study medication or placebo for up to 104 weeks. The study will measure how many flare-ups occur, how long it takes until the first flare-up happens, and how the disease affects daily life and breathing symptoms. Doctors will also track how many flare-ups require emergency room visits or hospital stays. Throughout the study, participants will continue taking their regular inhaled medications as prescribed by their doctor.

Participants in the study will be randomly assigned to receive either hydroxychloroquine sulfate or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. The study will monitor the participants throughout their pregnancy to observe any effects on pregnancy loss, premature birth, and other related outcomes. The medication will be taken orally in the form of film-coated tablets.

The trial will also assess the safety and tolerability of hydroxychloroquine sulfate for both the mother and the newborn. The study is expected to continue until the end of 2027, with participants being followed closely to gather comprehensive data on the effects of the treatment. The ultimate goal is to determine whether hydroxychloroquine sulfate can be a beneficial treatment option for improving pregnancy outcomes in women with antiphospholipid antibodies.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of this study is to find out if eRapa treatment can slow down disease progression in patients with familial adenomatous polyposis. Disease progression in this study means serious events related to the condition, such as the development of cancer, the presence of severely abnormal cells called high-grade dysplasia, the need for major surgery to remove parts of the intestine or digestive tract, or death from any cause. The study will also examine how eRapa affects the total size of polyps in both the upper digestive tract, specifically the duodenum, and the lower digestive tract, which includes the colon and any remaining portions of the rectum or surgically created pouch. Additionally, the study will track changes in polyp characteristics using a scoring system called the Spigelman stage score.

During the study, participants will take their assigned medication daily for up to 132 weeks, which is approximately two and a half years. They will undergo regular examinations using endoscopy, which is a procedure where a flexible tube with a camera is used to look inside the digestive tract, at various time points including 6, 12, 18, 24, 30, and 36 months. The study will monitor participants for any unwanted effects of the treatment and will measure how the treatment affects their quality of life using questionnaires. The study will also track how many participants need to stop taking the medication due to side effects.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The treatment involves regular injections of either maridebart cafraglutide or placebo, given in addition to standard heart failure treatments that participants are already receiving. The study will monitor how the medication affects participants’ heart health, particularly focusing on heart failure events that require medical attention and heart-related deaths.

During the study, researchers will track various aspects of participants’ health, including their heart function and quality of life. They will use questionnaires to assess how participants are feeling and functioning in their daily activities. The study will also monitor other important heart-related events such as myocardial infarction (heart attack) and ischemic stroke.

The aim is to find out whether adding the new medication to standard treatment lowers the chance of dying from heart‑related causes, being hospitalized for heart failure, or needing urgent care for heart failure.

Participants will receive a dose once a week for several months and will attend regular visits where simple checks such as blood pressure, weight, and short questionnaires are done. The study follows each person over time to see how often the listed heart events occur and to monitor safety through routine lab tests.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

During the study, participants will be monitored to see how well the different antibiotic treatments work to clear the infection and reduce symptoms such as fever. The course of the study involves comparing the effectiveness of the oral and injection combination against the existing hospital methods to determine if the new approach is just as effective in achieving a clinical cure.

During the trial, participants are assigned to receive either AZD0292 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being administered until the study is finished. The research will monitor how the medication moves through the body, a process known as pharmacokinetics, and track any pulmonary exacerbations, which are sudden increases in symptoms like coughing or shortness of breath. Participants will be monitored over a period of time to observe how the treatment affects the frequency of these lung symptom flare-ups.

Participants in the study may receive either Cyclogest, which is a form of progesterone delivered as a pessary through vaginal use, or a placebo. The luteal phase refers to the period in the menstrual cycle after ovulation occurs and before the next period begins, a time when hormone levels are critical for supporting a developing pregnancy. By comparing these two groups, the study aims to see how supplementation affects outcomes such as pregnancy rates and various health factors during pregnancy and birth.

Participants in this study are those who previously took part in earlier research trials. During this phase, the medication is given over an extended period to monitor how the body responds over time. This includes watching for any adverse events, which are unwanted or harmful medical occurrences, and observing the frequency of asthma exacerbations, which are sudden worsening of symptoms or attacks. The study also tracks changes in lung function and how the treatment affects daily life and breathing ease.

Participants in the study will receive either AZD5148 or a placebo. The medication will be given as an intravenous infusion, which means it is delivered directly into a vein through a needle or tube. This treatment is administered alongside standard care, which includes regular antibacterial drugs used to treat the current infection. During the study, individuals will be monitored to see if the infection returns within a specific period of time.

Participants in this study will be adults who are in the hospital with sepsis and have developed acute kidney injury. They must have been diagnosed with sepsis within seven days of being admitted to the hospital and must have developed kidney injury within a certain time after the sepsis diagnosis. Participants will need to be receiving medications to support their blood pressure because of the sepsis. The study medication must be given within a specific time window after the kidney injury is diagnosed.

During the study, doctors will measure how well the kidneys are working by checking various blood and urine tests. They will look at substances in the blood called creatinine and cystatin C, which show how well the kidneys are filtering. The study will also track whether participants need kidney replacement therapy, which is a treatment that does the work of the kidneys when they are not working properly. Other measurements will include how many days participants are alive without needing a breathing machine, how long they stay in the intensive care unit, and whether they need to return to the hospital after being discharged. The study will also measure the amount of AZD4144 in the blood to understand how the medication moves through the body.

During the study, participants will receive their assigned treatment for up to 28 weeks. The study will measure changes in the liver by looking at specific markers in the blood that show liver scarring and damage, such as the Enhanced Liver Fibrosis score and other substances that indicate how much scar tissue is forming in the liver. The study will also use a special ultrasound device that measures liver stiffness and fat content by sending gentle vibrations through the liver. Blood tests will check liver enzymes, which are proteins released when liver cells are damaged, and cholesterol levels. To understand effects on alcohol use, the study will measure a substance in the blood called phosphatidylethanol that indicates recent alcohol consumption, and participants will report their alcohol intake over time. The study will also carefully monitor any side effects that occur during treatment.

Participants in this study must be adults who have a history of drinking significant amounts of alcohol regularly for at least five years and who have evidence of liver damage based on blood test results. The study will compare how well the different medications work by measuring changes in liver health markers and alcohol use from the beginning to the end of the treatment period.

The purpose of this study is to evaluate the long-term effect of tozorakimab in reducing severe flare-ups of the lung disease in people who used to smoke. The study will also look at how safe the medication is when used over a longer period of time. This is an extension study, which means it is designed for people who have already participated in earlier studies of the same medication and completed their treatment without stopping early.

Participants who join this study will continue receiving the same type of treatment they were on in the previous study for up to 52 weeks. They will attend regular clinic visits where doctors will check their lung function, ask about any breathing problems or flare-ups, and monitor for any side effects. The study will track how often participants experience severe flare-ups that require emergency room visits or hospital stays, and will measure how long it takes before these serious episodes occur. Blood samples may be collected to measure the amount of medication in the body and to check how the immune system responds to the treatment.

The purpose of the study is to find out if giving this stem cell treatment through an infusion into the vein can help restore heart function in people who have been recently diagnosed with this type of heart failure. The study will compare how well the heart works in patients who receive the stem cell treatment versus those who receive the placebo. Patients in the study will receive their assigned treatment through infusions and will be followed for twelve months to see how their heart function changes over time.

During the study, doctors will measure various aspects of heart function using different methods. They will check the heart’s pumping ability and the size of the heart chambers at different time points after the treatment. Doctors will also assess how patients feel and function in their daily lives by checking their symptoms, their ability to walk for six minutes, and asking them to complete questionnaires about their quality of life. Blood tests will be performed to measure a substance that indicates heart stress. The study will also carefully monitor any unwanted effects or reactions that patients may experience to ensure the treatment is safe.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

During the study, participants will start taking both venetoclax and ART at the same time. The study will last for about one year, during which time researchers will carefully monitor participants for any side effects or health changes. Blood samples will be collected throughout the study to measure different things, including how much HIV virus is present in the blood and how many immune cells contain the virus. The researchers will look at special types of cells called CD4+ T cells, which are important immune cells that HIV attacks. They will use several laboratory tests to count how many of these cells contain HIV genetic material, which is called HIV-DNA and HIV RNA. Some of these tests have specific names like the Intact Proviral DNA Assay or IPDA, which helps identify cells that contain complete copies of the virus that could potentially produce new virus particles.

The researchers will also track how quickly the amount of virus in the blood decreases after treatment starts, and they will examine different types of immune cells including B cells and CD8+ T cells to see how they change during treatment. Throughout the study, all health problems and side effects will be recorded and assessed to determine whether they are related to the study medication. This information will help researchers understand whether venetoclax can be safely used together with standard HIV treatment and whether it might help reduce the amount of virus that stays hidden in the body even when people are taking their regular HIV medications.

The medication will be administered as a solution for injection containing 108 mg of vedolizumab. During the study, participants will receive regular injections of the medication for up to 24 months. The study will monitor how well children and teenagers tolerate long-term treatment with vedolizumab and track any side effects that may occur.

Throughout the study, doctors will watch for any health-related events and track the effectiveness of the treatment. They will pay special attention to how the medication affects the participants’ daily lives and overall well-being. The study includes regular check-ups to monitor the participants’ health and assess how well the digestive conditions are being controlled by the treatment.

The main purpose of this research is to determine if AZD6793 can reduce how often COPD symptoms get significantly worse (known as exacerbations) compared to placebo. The study will involve different groups of participants who will receive either different doses of AZD6793 or placebo tablets.

The treatment period will last 24 weeks, during which participants will take their assigned medication while continuing their regular breathing medications. Throughout the study, doctors will monitor participants’ breathing ability, symptoms, quality of life, and overall health. They will also check how the body handles the medication and watch for any potential side effects.

The study will compare SAR444336 to a placebo in patients whose microscopic colitis symptoms are currently under control with budesonide treatment. SAR444336 is given as a solution for injection that is administered under the skin (subcutaneous use). The treatment period will last for 20 weeks.

During the study, researchers will monitor how well participants maintain their improvement without using steroids. They will also track any side effects that may occur and measure how the body responds to the new medication. The study is designed so that neither the participants nor the doctors know who is receiving SAR444336 or placebo during the treatment period.

The purpose of this study is to determine how well AZD0780 works compared to placebo in lowering LDL cholesterol levels in patients who already take other cholesterol-lowering medications. The study will last for 52 weeks, during which participants will receive either AZD0780 or placebo in addition to their usual cholesterol-lowering treatments.

Throughout the study, researchers will monitor changes in various types of cholesterol and related substances in the blood, including apolipoprotein B, non-HDL cholesterol, total cholesterol, and lipoprotein(a). The main focus will be on measuring how much the LDL cholesterol levels change after 12 weeks of treatment.

The study aims to determine if the new chickenpox vaccine and Priorix work equally well when given as muscle injections compared to the standard under-the-skin method. The effectiveness will be measured by testing the body’s immune response to the vaccines through blood tests taken 43 days after vaccination.

During the study, participants will be monitored for common vaccination reactions like redness, pain, and swelling at the injection site, as well as general symptoms such as drowsiness, decreased appetite, irritability, and fever. They will also be checked for any rashes that may develop after vaccination. The total study duration will be 181 days, during which participants will have regular check-ups to monitor their health and any side effects.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.

The purpose of this research is to evaluate how well CSL787 works in preventing flare-ups of the disease and to determine the most effective dose. The medication will be given through a nebulizer, which is a device that turns liquid medicine into a fine mist that can be inhaled into the lungs. The study will last for up to 12 months.

During the study, participants will be randomly assigned to receive either different doses of CSL787 or a placebo through the nebulizer. The study will monitor how long it takes before participants experience their first disease flare-up and will also track other aspects of their lung health and overall well-being. This is a double-blind study, which means neither the participants nor the doctors conducting the study will know who is receiving which treatment.

The study medication comes in the form of film-coated tablets that are taken by mouth once daily. The treatment period lasts up to 76 weeks, during which participants will receive either BI 1291583 at a dose of 2.5 mg or a matching placebo. This is part of what is called a Phase III study, which is one of the final stages of testing a new medication before it can be approved for general use.

Throughout the study, participants will be monitored for improvements in their condition, particularly focusing on how often they experience pulmonary exacerbations (sudden worsening of respiratory symptoms that require antibiotic treatment). The study will also track changes in breathing tests and how the treatment affects participants’ quality of life related to their respiratory symptoms.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

The purpose of the study is to evaluate the safety of the new vaccine when given to young children. During the study, children will receive either the investigational vaccine or Varivax. The vaccines will be administered as a single dose through a small injection under the skin, known as a subcutaneous injection. The study will also involve the administration of other routine vaccines, such as the MMR vaccine (measles, mumps, and rubella), the HAV vaccine (hepatitis A), and, if applicable, the PCV (pneumococcal conjugate vaccine).

Throughout the study, researchers will monitor the children for any reactions to the vaccines, such as redness or swelling at the injection site, fever, or rash. These observations will help determine the safety of the new vaccine. The study will last several months, with follow-up visits to check on the children’s health and any potential side effects. The goal is to ensure that the new vaccine is safe for use in preventing chickenpox in young children.

The purpose of the study is to evaluate how well these vaccines work in producing an immune response and how safe they are for the participants. The study will involve receiving one of the vaccines through an injection. Participants will be monitored for their immune response to the vaccine strains, which are specific types of the flu virus, and for any side effects. The study will last for about a year, with the main focus on the immune response measured at 29 days after vaccination.

Participants will include healthy individuals or those with stable health conditions that increase their risk of complications from the flu. The study aims to ensure that the high-dose vaccine is as effective and safe as the other vaccines. The vaccines are administered using a pre-filled syringe, which is a single-use device. The study will help determine the best vaccine option for older adults to protect them against the flu.

The purpose of the study is to evaluate the safety and effectiveness of these treatments in preventing symptoms of COVID-19. Participants will receive either Sipavibart, EVUSHELD, or a placebo. The study will monitor participants over a period of time to see if they develop symptoms of COVID-19 and to assess any side effects from the treatments. The study will also look at how well the treatments work against different variants of the virus.

Participants in the study will be monitored for any side effects and the occurrence of COVID-19 symptoms. The study will also measure the levels of the treatments in the body over time. This research aims to provide valuable information on how these treatments can help protect people with immune system challenges from COVID-19.